Why the study?
Cellular therapies for myocardial fibrosis and cardiac regeneration face clinical translation pitfalls, prompting interest in cell-secreted extracellular vesicles.
Key points are not available for this paper at this time.
Design
Review
Vesicle-based therapy may circumvent cell therapy pitfalls in myocardial fibrosis; leaves open prospective validation before clinical adoption.
Heart disease remains an increasing major public health challenge in the United States and worldwide. A common end-organ feature in diseased hearts is myocardial fibrosis, which stiffens the heart and interferes with normal pump function, leading to pump failure. The development of cells for regenerative therapy has been met with many pitfalls on its path to clinical translation. Recognizing that regenerative cells secrete therapeutically bioactive vesicles has paved the way to circumvent many failures of cell therapy. In this review, we provide an overview of extracellular vesicles (EVs), with a focus on their utility as therapeutic agents for cardiac regeneration. We also highlight the engineering potential of EVs to enhance their therapeutic application.
No takes yet. Share an insight, caveat, or question.
Rogers et al. (2020) studied this question.
Synapse has enriched 4 closely related papers on similar clinical questions. Consider them for comparative context: